{"filings":[{"id":99629,"accession_number":"0001193125-26-214976","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.","Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.","Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.","Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99628,"accession_number":"0001213900-26-053369","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.","Cash & investments $731.6M; excludes $351M net proceeds from April offering.","R&D $35.7M, G&A $13.4M; total operating costs $49.9M.","Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026.","Closed public offerings raising $460M in Feb and $373.8M in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":10861000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99627,"accession_number":"0001193125-26-171731","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.","Net proceeds estimated at ~$350.9M after underwriting discounts and offering expenses.","Proceeds to fund general corporate purposes, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.","Joint bookrunners include Jefferies, TD Cowen, Piper Sandler; Citigroup also bookrunner.","Offering expected to close on April 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99626,"accession_number":"0001193125-26-164186","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nektar reports estimated cash and investments of $741.7M as of April 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities estimated at $741.7 million as of April 1, 2026.","Announcement is a preliminary estimate, not a comprehensive financial statement.","Amount based solely on information available as of April 20, 2026 filing date.","No other financial results or guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99625,"accession_number":"0001193125-26-162763","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.","SALT≤30 at wk52: 30.2% low, 35.0% high vs 8.4% placebo (p=0.023). SALT50: 37.7% low, 38.8% high vs 13.6% placebo.","94% of 31 patients completed 16-week extension; no discontinuations due to TEAEs. Injection site reactions mild-to-moderate, self-resolving within 5 days.","Nektar will submit results to a medical conference in 2026 and plans to advance rezpegaldesleukin into registrational trials in alopecia areata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115747,"accession_number":"0001213900-26-027026","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.","Net loss Q4 2025 $36.1M ($1.78/sh) vs net income $7.3M ($0.52/sh) in Q4 2024; full year net loss $164.1M.","Cash and investments $245.8M at Dec 31, 2025; subsequent $460M secondary offering and $44M ATM in Feb/Mar 2026.","Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata reported; Phase 3 to start Q2 2026.","Research collaboration with UCSF for NKTR-0165 in multiple sclerosis announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115746,"accession_number":"0001193125-26-049378","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.","Underwriters exercised full option for 1,034,482 additional shares; net proceeds ~$432M after discounts/expenses.","Proceeds for general corporate purposes including Phase 3 trial for rezpegaldesleukin and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115745,"accession_number":"0001193125-26-044751","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nektar Therapeutics reports $229.1M cash and investments as of Jan 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities totaled approximately $229.1 million as of January 31, 2026.","Announcement made on February 10, 2026 via a Regulation FD disclosure.","The amounts are estimates based on information available as of the announcement date.","Nektar Therapeutics (ticker: NKTR) listed on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115744,"accession_number":"0001193125-26-043755","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.","EASI-100 increased 2-5 fold: from 4% to 22% (monthly) and 9% to 18% (quarterly) in re-randomized patients.","Discontinuation rate due to AEs was 3.5%; injection site reactions mostly mild; no new safety concerns.","FDA alignment on Phase 3 design: 24 µg/kg Q2W induction, co-primary endpoints; start Q2 2026.","New responses at Week 52: 51% new EASI-75 (monthly) and 39% (quarterly) support prolonged therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115743,"accession_number":"0001213900-26-008210","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nektar enters quiet period ahead of Phase 2b REZOLVE-AD maintenance data; data expected in February 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quiet period begins January 27, 2026 and continues until public announcement of the maintenance data.","Maintenance Data are from the 36-week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin.","Next investor communication planned for February 2026 at the time of data presentation.","This quiet period is consistent with prior quiet periods for REZOLVE studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132169,"accession_number":"0001193125-25-320009","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).","Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.","Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.","Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.","Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132168,"accession_number":"0001213900-25-113606","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nektar Therapeutics Chief Legal Officer Mark A. Wilson to Depart; Elizabeth Zhang to Succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025.","Elizabeth Zhang, Vice President of Legal and Corporate Counsel, will take over Wilson's responsibilities.","Zhang joined Nektar in 2021 and previously worked at Cravath, Swaine & Moore and Gibson, Dunn & Crutcher.","Zhang holds a BA from Harvard College, an MS from the University of Oxford, and a JD from Harvard Law School.","Wilson's departure is not the result of any disagreement with Nektar on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132167,"accession_number":"0001213900-25-107821","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).","In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.","Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.","Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.","Top-line Phase 2b data in alopecia areata expected December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132166,"accession_number":"0001213900-25-107180","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.","Revenue $11.8M, down from $24.1M YoY due to sale of Huntsville facility in Dec 2024.","Cash & marketable securities $270.2M as of Sep 30, 2025; includes $107.2M from July secondary offering.","R&D expense $27.3M vs $35.0M YoY; focus on rezpegaldesleukin, NKTR-0165, NKTR-422.","FDA granted Fast Track for rezpegaldesleukin in severe alopecia areata; topline data expected Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":33425000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148742,"accession_number":"0001213900-25-088792","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).","High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.","Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.","Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.","Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148741,"accession_number":"0001213900-25-073100","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.","Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.","Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.","FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).","REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":21635000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148740,"accession_number":"0001193125-25-154062","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nektar Therapeutics prices $100M public offering at $23.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nektar prices 4,255,320 shares at $23.50/share for gross proceeds of $100M.","Net proceeds estimated at $93.7M ($107.8M if underwriters' option exercised in full).","Offering expected to close July 2, 2025; Jefferies and Piper Sandler are joint bookrunners.","Proceeds to fund R&D, clinical development, manufacturing, and other general corporate purposes.","Underwriters have a 30-day option to purchase up to an additional 638,298 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167620,"accession_number":"0001213900-25-059115","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nektar Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on April 3, 2025 for bid price below $1.00.","Regained compliance on June 23, 2025 after 10 consecutive trading days above $1.00.","Nasdaq confirmed compliance in a letter dated June 24, 2025.","Company continues to trade on The Nasdaq Capital Market under symbol NKTR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167619,"accession_number":"0001213900-25-056909","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).","EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).","Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.","Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.","On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167618,"accession_number":"0001213900-25-052141","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nektar boosts authorized shares to 390M, completes 1-for-15 reverse split effective June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 300M to 390M, effective June 6, 2025, stockholder-approved May 23, 2025.","Reverse stock split at 1-for-15 ratio effective 11:59 p.m. ET June 8; split-adjusted trading starts June 9 under NKTR.","Fractional shares rounded up at DTC for directly held shares; rounded down to nearest whole share for equity awards.","Total authorized shares remain at 390M after reverse split due to prior increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167617,"accession_number":"0001213900-25-051191","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nektar Therapeutics announces 1-for-15 reverse stock split effective June 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-15 reverse stock split effective June 8, 2025 at 11:59 p.m. ET.","Stockholders authorized reverse split ratio up to 1:40 at May 23 annual meeting; Board selected 1:15.","Split-adjusted trading begins June 9 under symbol NKTR with new CUSIP 640268306.","No fractional shares issued; rounding up for DTC participants, down for stock awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167616,"accession_number":"0001213900-25-047890","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nektar shareholders approve authorized share increase to 390M and reverse split authorization","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).","Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).","Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).","Directors Diana Brainard and R. Scott Greer elected; other directors continue.","Ernst & Young ratified as auditor; say-on-pay advisory resolution passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167615,"accession_number":"0001213900-25-041085","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.","Revenue $10.5M, down from $21.6M YoY due to sale of Huntsville facility.","Net loss $50.9M ($0.24/share) vs $36.8M ($0.19) in Q1 2024; non-GAAP loss $46.4M.","Topline Phase 2 data for rezpegaldesleukin in atopic dermatitis expected June 2025.","FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":10460000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167614,"accession_number":"0001213900-25-029002","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nektar receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 3, 2025 for non-compliance with minimum bid price rule.","Must regain compliance by September 30, 2025; closing bid price must be at least $1.00 for 10 consecutive days.","If not compliant by deadline, Nasdaq may grant second 180-day grace period subject to conditions.","Company intends to monitor bid price and consider options to regain compliance; no guarantee of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184903,"accession_number":"0001013762-25-004236","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nektar enters ATM equity distribution agreement for up to $75M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM equity distribution agreement with Piper Sandler and BTIG allows sale of up to $75M of common stock.","Shares sold via at-the-market offerings on Nasdaq; agents receive 3.0% commission on gross proceeds.","Company has no obligation to sell any shares; either party may suspend or terminate the offering.","Registration statement on Form S-3 filed on March 28, 2025, for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184902,"accession_number":"0001213900-25-023220","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.","Revenue Q4 $29.2M (+22% YoY); cash $269.1M, expected to fund operations into Q4 2026.","Rezpegaldesleukin Phase 2b topline data: atopic dermatitis in Q2 2025, alopecia areata in Q4 2025.","FDA granted Fast Track designation for rezpegaldesleukin in moderate-to-severe atopic dermatitis.","Sold PEGylation manufacturing business for $90M enterprise value ($70M cash + $20M equity)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184901,"accession_number":"0001213900-25-016278","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TrialNet will conduct a Phase 2 randomized, placebo-controlled trial in ~70 adults and children with new onset stage 3 T1D.","Nektar supplies rezpegaldesleukin, retains all program rights; TrialNet funds the study via NIH.","Study aims to preserve beta-cell function using MMTT-measured C-peptide over 12 months; initiation targeted for 2025.","Rezpegaldesleukin is also in Phase 2b trials for atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184900,"accession_number":"0001213900-25-010085","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.","Brian Kotzin, MD, appointed interim CMO; he previously served as strategic advisor for rezpegaldesleukin program since April 2023.","Kotzin has over 40 years immunology experience; was VP at Amgen and held academic positions; will assist search for permanent CMO.","Kotzin currently serves on boards of Argenx SE, Biora Therapeutics, and Genascence Corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201496,"accession_number":"0001213900-24-104240","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Nektar completes sale of Huntsville manufacturing facility to Ampersand affiliate","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Closed disposition of Huntsville, AL manufacturing facility and related assets to an affiliate of Ampersand Capital Partners.","Transaction completed on December 2, 2024, as previously announced on November 4, 2024.","Purchaser assumed certain related liabilities; no financial terms disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201495,"accession_number":"0001213900-24-095423","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.","Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.","Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).","R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.","Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201494,"accession_number":"0001213900-24-093768","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Nektar to sell Huntsville PEGylation plant to Ampersand for $90M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).","Expected close by Dec 2, 2024; all Huntsville employees offered jobs at new co.","Nektar retains existing royalty/milestone rights; enters supply agreements for PEG reagents.","Sale not subject to financing; extends Nektar cash runway into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217495,"accession_number":"0001213900-24-066630","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).","Cash and investments $290.6M at June 30, 2024, down from $329.4M at Dec 31, 2023; runway into Q3 2026.","Revenue Q2 2024 $23.5M vs $20.5M Q2 2023; R&D expense flat at $29.7M; non-cash restructuring/impairment $13.3M.","Rezpegaldesleukin Phase 2b enrollment on track; topline data expected H1 2025 (atopic dermatitis) and mid-2025 (alopecia areata)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":45128000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237375,"accession_number":"0001213900-24-050365","cik":906709,"company_name":"NEKTAR THERAPEUTICS","ticker":"NKTR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nektar shareholders elect three directors, approve 8M share increase, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Jeff Ajer, Robert B. Chess, Roy A. Whitfield with broker non-votes of 46.7M each.","Approved amendment to 2017 Performance Incentive Plan adding 8M shares; 86.5M for, 7.5M against.","Ratified Ernst & Young as independent auditor for FY2024: 139M for, 1.6M against, 6M abstain.","Non-binding say-on-pay approved: 87M for, 6.7M against, 6.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2209606267.4313607,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}